14 January 2025
14 January 2025
CEO Albert Bourla expressed modest optimism for Pfizer’s 2025 revenues at JPM 2025, supported by plans to prioritize R&D in oncology and obesity.
NVIDIA starts 2025 by announcing a trio of partnerships and a research collaboration to boost healthcare sector presence.
After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the biotech’s current shareholders.
The proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvae’s launch in postpartum depression.
Amgen CEO Robert Bradway said the company's obesity drug could find its space in the market due to once-monthly dosing and expansion of manufacturing capabilities.
The PDUFA action date for the more convenient autoinjector is set for August 2025.
US-based biotech Normunity plans to initiate a Phase I clinical trial of NRM-823 in the second half of 2025.
LEO Pharma is eligible to receive up to $1.7bn in total payments, which include a $250m upfront payment.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
